Guerbet Logo

Guerbet

Offers medical imaging solutions, from contrast agents to AI, for healthcare professionals.

GBT | PA

Overview

Corporate Details

ISIN(s):
FR0000032526 (+3 more)
LEI:
969500WV1U1WQ059L135
Country:
France
Address:
15 RUE DES VANESSES, 93420 VILLEPINTE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Guerbet is a global leader in medical imaging, specializing in diagnostic and interventional imaging solutions for healthcare professionals. Since its establishment in 1926, the company has developed and commercialized a comprehensive portfolio that includes contrast agents, medical devices, delivery systems, and digital and AI-powered solutions. Guerbet's products are utilized to improve the diagnosis and treatment of major disease areas such as cancer, as well as cardiovascular, inflammatory, and neurodegenerative diseases. The company focuses on providing innovative and safe solutions to enhance patient care and support radiology professionals worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-02 17:45
Business and Financial Review
GUERBET : Ajustement des objectifs financiers 2025.
French 157.0 KB
2025-12-02 17:45
Earnings Release
GUERBET : Adjustment of 2025 financial targets.
English 150.5 KB
2025-11-24 17:44
Declaration of Voting Results & Voting Rights Announcements
GUERBET : Nombre d'actions et de droits de vote composant le capital de la soci…
French 153.1 KB
2025-11-19 13:47
Report Publication Announcement
GUERBET : Calendrier financier de l’exercice 2026
French 198.7 KB
2025-11-19 13:47
Report Publication Announcement
GUERBET : Financial agenda for 2026
English 172.2 KB
2025-10-23 17:45
Earnings Release
Guerbet : Chiffre d’affaires au 30 septembre 2025. Retour de la croissance au 3…
French 294.9 KB
2025-10-23 17:45
Earnings Release
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmat…
English 305.6 KB
2025-10-14 17:30
Declaration of Voting Results & Voting Rights Announcements
GUERBET : Nombre d'actions et de droits de vote composant le capital de la soci…
French 158.6 KB
2025-09-24 17:45
Earnings Release
Guerbet : H1 2025 results : H1 revenue: €387.8 million, down 5.4% at CER and on…
English 524.6 KB
2025-09-24 17:45
Earnings Release
Guerbet : Résultats semestriels 2025 : Chiffre d’affaires du 1er semestre : 387…
French 496.3 KB
2025-09-22 17:45
Board/Management Information
Guerbet : Evolution de la Direction Générale
French 134.4 KB
2025-09-22 17:45
Board/Management Information
Guerbet : Change in General Management
English 113.8 KB
2025-09-18 17:45
Declaration of Voting Results & Voting Rights Announcements
GUERBET : Nombre d'actions et de droits de vote composant le capital de la soci…
French 159.1 KB
2025-09-15 17:50
Earnings Release
Guerbet : Ajustement des objectifs financiers annuels 2025
French 209.3 KB
2025-09-15 17:50
Earnings Release
Guerbet : Adjustment of 2025 full-year financial targets
English 186.1 KB

Automate Your Workflow. Get a real-time feed of all Guerbet filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Guerbet

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Guerbet via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-19 N/A Other Buy 142 4,989.31 EUR
2024-08-15 N/A Other Buy 195 6,678.75 EUR
2024-08-12 N/A Other Buy 1,000 34,350.00 EUR
2024-04-18 N/A Other Sell 550 17,699.00 EUR
2023-11-30 N/A Other Sell 700 12,684.00 EUR
2023-11-03 N/A Other Buy 1 17.92 EUR
2023-10-30 N/A Other Buy 1,000 17,000.00 EUR
2023-10-25 N/A Other Buy 1,000 16,800.00 EUR
2023-10-24 N/A Other Buy 1,000 16,460.90 EUR
2023-05-04 N/A Other Buy 300 4,938.00 EUR

Peer Companies

Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
Trevi Therapeutics, Inc. Logo
Clinical-stage biopharma developing an oral therapy for chronic cough in IPF and RCC.
United States of America
TRVI
TRINITY BIOTECH PLC Logo
Develops and markets clinical diagnostic test kits and biosensors for labs and point-of-care.
United States of America
TRIB
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC
Tvardi Therapeutics, Inc. Logo
Developing oral STAT3 inhibitors to treat cancers and fibrosis-driven diseases.
United States of America
TVRD
UCB Logo
UCB
Biopharma firm developing treatments for severe neurological and immunological diseases.
Belgium
UCB
Ultragenyx Pharmaceutical Inc. Logo
Develops and commercializes novel therapies for rare and ultra-rare genetic diseases.
United States of America
RARE
Develops biopharma therapies for endocrinology, ophthalmology, and dermatology needs.
Hong Kong
690
Unicycive Therapeutics, Inc. Logo
A clinical-stage biotech developing novel treatments for kidney diseases, led by oxylanthanum carbonate.
United States of America
UNCY

Talk to a Data Expert

Have a question? We'll get back to you promptly.